The combination of antiangiogenic agents such as the anti‐VEGF monoclonal antibody bevacizumab with everolimus might also be a feasible approach because the VEGF signaling pathway acts through the PI3K/mTOR pathway (Fig. 1), and the PI3K pathway is critical for endothelial cell activation and tumor angiogenesis 56. This evidence concerns the gene VEGFA and neoplasm.